Quantuvis

When navigating market changes, it's important to keep several important aspects in mind:     📌 Speed of Insights to Action - ability to extract insights from your data and confidently comprehend the financial situation and its impact on profitability through the platform's robust capabilities and connected intelligence.   📌 Validation of your Overall Strategy - aligning the execution plan with your overarching business strategy to ensure that the actions taken will have a significant and positive effect on your business objectives.  ✅ We will discuss this and more during our upcoming webinar. Register today to secure your spot - https://lnkd.in/gPWqb884.

📢 Are you attending the Prime Therapeutics Specialty Summit in NYC next week? Gregory Lee and Corrado Panno from Quantuvis will be present at the event and are looking forward to networking opportunities. ✅ Reach out to us if you would like to schedule some time for an in-person meeting.

📢 Join us for our upcoming thought leadership webinar tailored for Finance Leaders presented by Sandeep Patel - CEO, Quantuvis; Global Health Advisor, Bain; and former Executive and General Management leader, Cigna - https://lnkd.in/gPWqb884 📊 As market headwinds challenge the traditional experience-driven operating models and as the data universe continues to become more complex, this exclusive event will focus on providing valuable insights into essential tools to effectively tackle these headwinds.  📌 Regulatory changes, Payer & PBM consolidation, and market complexity make it necessary to integrate technological evolution and AI into the decision-making process to supplement traditional experience-driven operating models and preserve GTN.

📢 Following robust success in securing a significant market share within the competitive Humira biosimilar sector and with a pipeline of key product launches underway, Sandoz, a subsidiary of Novartis, has revised its full-year sales guidance. The boost was driven by the drugmaker’s clutch of biosimilars, which together saw an "exceptional" growth rate of 29%. 🔊 Today’s new biosimilars are entering highly competitive markets where PBMs have well-established contracts with reference drugs. PBMs are accustomed to the substantial revenue from rebates provided by these brands, and many of their contracts are likely market share based.  📉 To succeed in the biosimilar space, it will be crucial to develop effective channel strategies and tailored solutions to ensure access and uptake. This requires getting payer contracts right from the outset.  At Quantuvis, we’ve developed a solution specifically designed for market access teams. By leveraging your existing data assets and invoice data — we combine these sources into a cloud-based technology platform to enable in-house analytics.  Reach out to us today if you want to learn more! # MarketOpportunit # StrategyDevelopment, #ContractDevelopment 

📈 In recent trends, there has been a noticeable shift in focus. The spotlight is moving away from oncology drugs, as medications for obesity and diabetes are gaining prominence.    🔉 For example, it is widely acknowledged that pharmaceuticals targeting obesity, developed by Novo Nordisk and Eli Lilly, are experiencing notable growth and are poised to sustain this momentum. According to a recent report from Evaluate, it is anticipated that obesity-focused products will surpass several long-standing medications to secure positions among the world's best-selling drugs by the close of the current decade.    ✅ Quantuvis solutions can help you to facilitate the identification of market trends, comprehension of contract opportunities, and the alignment of corresponding strategies. Reach out to us to learn how you can unlock the potential of your team by leveraging advanced analytics and insights. #oncology #obesity #marketaccess

Almost 2 years since #IRA was signed, the negotiated Medicare prices for the first 10 drugs have now been published with discounts off WAC ranging from 38-79%.

📈 The Centers for Medicare & Medicaid Services recently released the latest projections for U.S. healthcare spending. These data provide insight into how the Inflation Reduction Act will impact U.S. healthcare spending and prescription drug costs in 2032. The changes to the Medicare Part D program under the Inflation Reduction Act, coupled with upcoming demographic shifts, will significantly affect future spending by government programs and consumers.    📢 How is your team preparing for the potential impact of the Inflation Reduction Act on your market access strategy? Reach out to Quantuvis, and we would be happy to share how we support our clients. #marketaccess #ira

📌 The global dermatology drugs market is expected to increase from $40.55 billion in 2023 to $70.59 billion by 2030, with a compound annual growth rate (CAGR) of 8.2%. This growth is being driven by new medications and patient subpopulations. 🔊 Recently, it was announced that LEO Pharma has received its first approval for a drug to treat chronic hand eczema, and it is likely to obtain EU approval for delgocitinib, a treatment for chronic hand eczema, in the coming weeks. Delgocitinib is considered the company's top pipeline prospect.     ✅ These market events make it a highly competitive and dynamic field that is critical to get pricing, contracting, and access right at launch and in response to new entrants.   If you want to learn more about how Quantuvis helps its clients ensure success in planning and executing their access and contract strategy, even in highly ambitious and evolving therapeutic areas, feel free to reach out to us.    #marketaccess

🔊 The market for osteoporosis, the prevailing metabolic bone disorder globally characterized by reduced bone mineral density and increased fracture risk, is set to experience a significant growth rate - putting Amgen and its rivals in line to capture the additional $7 billion in annual sales that are forecast by 2033.    🔎 As the market is shifting many generic drug makers are targeting the market. Teva launched a generic copy of Lilly’s Forteo in the U.S. in November. Ambio and Apotex won FDA approval for their generic version of Forteo weeks later.     💡 In this type of evolving competitive market, what tools do you have in place to handle contract deal analytics? At Quantuvis we have a number of solutions that can help you determine if your contracts are profitable or if you should walk away.   Using Quantuvis’ solutions our clients are able to find the right position when contracting with payers, PBMs, and other trading partners. Reach out to us directly if you want to learn more! #marketaccess #pricing #pullthrough 

🔊 The top three PBMs felt the heat at a hearing of the House Oversight Committee, when testifying about rebate pass-through to plan sponsors. The tough questioning was fueled by a report published ahead of the hearing, which concluded that the actions of the PBMs "inflate prescription drug costs and interfere with patient care for their own financial benefit." The pharmaceutical industry has cited similar reports about the pressure on drug list prices driven by PBM rebates.     📈 This uncertainty of market and regulatory changes encourages many pharmaceutical companies to have a system in place that allows them to proactively react to these pressures and adjust their market access strategies.    ✅ We at Quantuvis understand the critical importance of optimizing product access and contract value, reducing revenue leakage, and maximizing team efficiency. Reach out to Quantuvis to learn more about our solutions, that are modularized to meet your organization’s individual needs.  #analytics  #marketaccess #rebate #rebatemanagement #pbm  #revenueleakage